Aligos Therapeutics Inc (ALGS)

$8.24 +1.06 (14.76%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	43.90M
Revenue (ttm)	3.95M
Net Income (ttm)	-131.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,321.77%
Debt to Equity Ratio	0.00

Volume	137,500
Avg Vol	146,116
Day's Range	N/A - N/A
Shares Out	6.11M
Stochastic %K	73%
Beta	2.69
Analysts	Strong Sell
Price Target	$117.50

Company Profile

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-12575...

Industry: Biotechnology

Sector: Healthcare

Phone: 800-466-6059

Website: www.aligos.com

Address:

One Corporate Drive, 2nd Floor, South San Francisco, United States